CD4 and hepatocellular carcinoma: Thus, targeting inflammation—such as targeting the gut-live axis thus dampening immune cell activation; targeting the inflammatory cells, e.g., TAM, monocyte, CD4+ T cells, CD8+ T cells, DCs; targeting the key inflammatory pathways—is believed to be an attractive therapeutic strategy in the management of HCC.